Laszlo KissExecutive Director at Pfizer Ventures
Laszlo Kiss, PHD is Executive Director at Pfizer Ventures. Laszlo is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Accelerator NYC, Aquinnah, Autifony, Cortexyme, Magnolia, Simcha, System1, Triplet and Yumanity. Laszlo has over 20 years of drug discovery, development and management experience. He has a successful track record in leading CNS, CV and Rare Disease drug discovery programs from early exploratory research through clinical development. Prior to joining Pfizer, Laszlo held a variety of roles at Bristol-Myers Squibb, Essen Biosciences, and Merck & Co.